Recent Company News

• 10:58 PM ET Mar 24, 2026
  

  Street Takeaways - Wuxi Biologics (Cayman) FY earnings (HK$32.72, +0.32)

• 05:55 AM ET Mar 24, 2026
  

  StreetAccount Metrics Recap - Wuxi Biologics (Cayman) FY Earnings (HK$33.88, 0.00)

• 05:50 AM ET Mar 24, 2026
  

  Wuxi Biologics (Cayman) reports FY adjusted net income attributable CNY5.64B vs FactSet CNY5.05B (HK$33.88, 0.00)

• 12:19 PM ET Mar 19, 2026
  

  StreetAccount Consensus Metrics Preview - Wuxi Biologics (Cayman) FY Earnings (HK$34.94, 0.00)

• 09:58 PM ET Feb 09, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 03:22 AM ET Feb 12, 2026
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (40 total)

• 06:34 PM ET Feb 10, 2026
  

  Wuxi Biologics (Cayman) reports FY preliminary net income attributable CNY4.91B vs FactSet CNY4.49B [13 est, CNY3.71-5.20B] (HK$40.02, 0.00)

• 01:03 AM ET Feb 04, 2026
  

  StreetAccount Sector Summary - China Healthcare January Recap

• 10:16 PM ET Feb 02, 2026
  

  Wuxi Biologics and Vertex Pharmaceuticals to jointly develop a trispecific T-cell Engager for treating B-cell mediated autoimmune diseases (HK$37.02, +0.02)